Literature DB >> 29027405

Safety of fertility-sparing surgery for stage I ovarian clear cell carcinoma.

Jeong Yeol Park1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29027405      PMCID: PMC5641537          DOI: 10.3802/jgo.2017.28.e91

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


× No keyword cloud information.
Fertility-sparing surgery can be performed safely in selected women with stage I epithelial ovarian cancer [1]. However, the safe indications for fertility-sparing surgery for stage I epithelial ovarian cancer vary from study to study. There has never been a well designed randomized controlled trial. Recent largest 2 retrospective studies reported different indications. In a Japanese study, fertility-sparing surgery can be performed safely only in stage IA, IC, grade 1–2, non-clear cell carcinoma and stage IA clear cell carcinoma [2]. In an Italian study, in the contrary, fertility-sparing surgery can be performed safely in all patients with stage I epithelial ovarian cancer except grade 3 disease [3]. In addition, indications for safe fertility-sparing surgery for stage I epithelial ovarian cancer vary slightly from one treatment guideline to another. The National Comprehensive Cancer Network (NCCN) treatment guideline suggests that fertility-sparing surgery can be performed in all patients with stage IA and IC epithelial ovarian cancer [4], but Gynecologic Cancer InterGroup (GCIG) consensus review suggests that fertility-sparing surgery is not recommended for stage IC, clear cell carcinoma [5]. The main issue is whether fertility-sparing surgery is safe for stage I ovarian clear cell carcinoma (OCCC). However, only few studies introduced this issue until now, and all of them included only small number of patients with stage I OCCC [267]. In this issue, Nasioudis et al. [8] reported the safety of fertility-sparing surgery in stages IA and IC OCCC in a large cohort using the National Cancer Institue's Surveillance, Epidemiology, and End Results (SEER) data base in this issue. This study includes the largest cohort of stage I OCCC treated with fertility-sparing surgery ever reported. The preservation of uterus and ovary in stage I OCCC did not affect on the survival outcomes in this cohort. The indications for fertility-sparing surgery can be extended to stage I OCCC [8]. The main reason for not recommending fertility-sparing surgery in OCCC was the concern about poor survival outcomes. However, recent studies suggested that the survival outcomes of early stage OCCC are similar with other histologic types [59]. Therefore, the indication for fertility-staging surgery for OCCC needs not to be different from other histologic types. Nasioudis et al.'s study [8] supported this well. However, it is not clear whether fertility-sparing surgery was performed in young women who want to preserve their fertility in this study. Further studies are needed to confirm the safety of fertility-sparing surgery in OCCC.
  8 in total

1.  Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible?

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mika Mizuno; Satoyo Hosono; Michiyasu Kawai; Tetsuro Nagasaka; Fumitaka Kikkawa
Journal:  Hum Reprod       Date:  2011-10-20       Impact factor: 6.918

Review 2.  Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.

Authors:  Aikou Okamoto; Rosalind M Glasspool; Seiji Mabuchi; Noriomi Matsumura; Hiroyuki Nomura; Hiroaki Itamochi; Masashi Takano; Tadao Takano; Nobuyuki Susumu; Daisuke Aoki; Ikuo Konishi; Alan Covens; Jonathan Ledermann; Delia Mezzanzanica; Delia Mezzazanica; Christopher Steer; David Millan; Iain A McNeish; Jacobus Pfisterer; Sokbom Kang; Laurence Gladieff; Jane Bryce; Amit Oza
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

3.  Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection.

Authors:  Toyomi Satoh; Masayuki Hatae; Yoh Watanabe; Nobuo Yaegashi; Osamu Ishiko; Shoji Kodama; Satoshi Yamaguchi; Kazunori Ochiai; Masashi Takano; Harushige Yokota; Yosuke Kawakami; Sadako Nishimura; Daiki Ogishima; Shunsuke Nakagawa; Hiroaki Kobayashi; Tanri Shiozawa; Toru Nakanishi; Toshiharu Kamura; Ikuo Konishi; Hiroyuki Yoshikawa
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

4.  Outcomes of fertility-sparing surgery among young women with FIGO stage I clear cell carcinoma of the ovary.

Authors:  Jeong-Yeol Park; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  Int J Gynaecol Obstet       Date:  2016-03-11       Impact factor: 3.561

Review 5.  Fertility-sparing surgery for young women with early-stage epithelial ovarian cancer.

Authors:  Joo-Hyun Nam; Jeong-Yeol Park
Journal:  Gynecol Obstet Invest       Date:  2013-06-06       Impact factor: 2.031

6.  Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series.

Authors:  R Fruscio; S Corso; L Ceppi; D Garavaglia; A Garbi; I Floriani; D Franchi; M G Cantù; C M Bonazzi; R Milani; C Mangioni; N Colombo
Journal:  Ann Oncol       Date:  2012-09-03       Impact factor: 32.976

7.  Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?

Authors:  Dimitrios Nasioudis; Eloise Chapman-Davis; Melissa K Frey; Steven S Witkin; Kevin Holcomb
Journal:  J Gynecol Oncol       Date:  2017-07-03       Impact factor: 4.401

8.  Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review.

Authors:  Morikazu Miyamoto; Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Hitoshi Tsuda; Kenichi Furuya
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

  8 in total
  1 in total

1.  Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis.

Authors:  Masato Yoshihara; Hiroaki Kajiyama; Satoshi Tamauchi; Shiro Suzuki; Kunihiko Takahashi; Shigeyuki Matsui; Fumitaka Kikkawa
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.